Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy

Overview

Journal Arch Pathol Lab Med

Specialty Pathology

Date 2020 Mar 10

PMID 32150459

Citations 28

Authors

Irina Sobol

Carol L Chen

Syed S Mahmood

Alain C Borczuk

Affiliations

Soon will be listed here.

Abstract

Context.—: Cardiac complications of immune checkpoint inhibitor therapy are rare, but reports of myocarditis are increasing. The findings have been described in case reports as lymphocytic myocarditis, but its histopathology is underreported.

Objective.—: To review the histology of myocardial biopsy-proven cases of immune checkpoint-associated myocarditis and provide immunohistochemical characterization of the inflammatory infiltrate.

Design.—: We have encountered 6 patients with biopsy-proven myocarditis in conjunction with therapy using anti-programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) agents with and without cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitors and characterized the histopathology and immune cell profile.

Results.—: The myocarditis was multifocal/diffuse and characterized by a predominant CD163-positive histiocytic infiltrate, with an associated CD8+ and PD-1+ T-lymphocytic infiltrate, some of which were granzyme B positive. Cardiac myocytes showed immunoreactivity for PD-L1 in areas of injury, confirmed using 2 different anti-PD-L1 clones. Four of 6 patients recovered from their cardiac injury. One patient had residual tachycardia-bradycardia syndrome and 1 patient expired.

Conclusions.—: The diffuse lymphohistiocytic myocarditis associated with this therapy is relatively distinctive, and this diagnosis is strongly suggested based on the histopathologic findings in the correct clinical setting.

Citing Articles

Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC).

Abulizi A, Yan G, Xu Q, Muhetaer R, Wu S, Abudukelimu K Sci Rep. 2024; 14(1):25919.

PMID: 39472591 PMC: 11522629. DOI: 10.1038/s41598-024-75099-5.

The Good (Tumor Killing) and the Bad (Cardiovascular Complications) of Immunologic Checkpoint Inhibitors.

Gamero M, Patel A, Storozynsky E Curr Cardiol Rep. 2024; 26(12):1487-1498.

PMID: 39441327 PMC: 11668830. DOI: 10.1007/s11886-024-02147-x.

Expect the unexpected: fulminant myocardial cytotoxic Injury from Trabectedin.

Tsay A, Satish M, Corley E, Ezema A, DeJesus N, Wisely S Cardiooncology. 2024; 10(1):70.

PMID: 39407287 PMC: 11476495. DOI: 10.1186/s40959-024-00257-7.

Myasthenia gravis and myocarditis induced by chemoimmunotherapy in locally advanced gastric cancer: A case report.

Wang Y, Sun Z, Wang X, Liu F, Wu Y, Wei Q Exp Ther Med. 2024; 28(5):426.

PMID: 39301255 PMC: 11412106. DOI: 10.3892/etm.2024.12715.

Immune Checkpoint Inhibitor-Related Myocarditis: A Case Series and Literature Review.

Chu C, Liang H, Lien M, Wu H Acta Cardiol Sin. 2024; 40(4):445-450.

PMID: 39045377 PMC: 11261368. DOI: 10.6515/ACS.202407_40(4).20240401A.

References

Grabie N, Gotsman I, DaCosta R, Pang H, Stavrakis G, Butte M . Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation. 2007; 116(18):2062-71. DOI: 10.1161/CIRCULATIONAHA.107.709360. View

Heinzerling L, Ott P, Hodi F, Husain A, Tajmir-Riahi A, Tawbi H . Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016; 4:50. PMC: 4986340. DOI: 10.1186/s40425-016-0152-y. View

Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A . Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015; 3:11. PMC: 4404586. DOI: 10.1186/s40425-015-0057-1. View

Johnson D, Balko J, Compton M, Chalkias S, Gorham J, Xu Y . Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016; 375(18):1749-1755. PMC: 5247797. DOI: 10.1056/NEJMoa1609214. View

Tajiri K, Aonuma K, Sekine I . Immune checkpoint inhibitor-related myocarditis. Jpn J Clin Oncol. 2017; 48(1):7-12. DOI: 10.1093/jjco/hyx154. View

Yamaguchi S, Morimoto R, Okumura T, Yamashita Y, Haga T, Kuwayama T . Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab. Can J Cardiol. 2018; 34(6):812.e1-812.e3. DOI: 10.1016/j.cjca.2018.03.007. View

Reuben A, Macedo M, McQuade J, Joon A, Ren Z, Calderone T . Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology. 2017; 6(12):e1361097. PMC: 5706622. DOI: 10.1080/2162402X.2017.1361097. View

Moslehi J, Salem J, Sosman J, Lebrun-Vignes B, Johnson D . Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018; 391(10124):933. PMC: 6668330. DOI: 10.1016/S0140-6736(18)30533-6. View

Mahmood S, Fradley M, Cohen J, Nohria A, Reynolds K, Heinzerling L . Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018; 71(16):1755-1764. PMC: 6196725. DOI: 10.1016/j.jacc.2018.02.037. View

10.

Eggermont A, Chiarion-Sileni V, Grob J, Dummer R, Wolchok J, Schmidt H . Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015; 16(5):522-30. DOI: 10.1016/S1470-2045(15)70122-1. View

11.

Matson D, Accola M, Rehrauer W, Corliss R . Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab. J Forensic Sci. 2017; 63(3):954-957. DOI: 10.1111/1556-4029.13633. View

12.

Overman M, Lonardi S, Wong K, Lenz H, Gelsomino F, Aglietta M . Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018; 36(8):773-779. DOI: 10.1200/JCO.2017.76.9901. View

13.

Postow M, Chesney J, Pavlick A, Robert C, Grossmann K, McDermott D . Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372(21):2006-17. PMC: 5744258. DOI: 10.1056/NEJMoa1414428. View

14.

Nghiem P, Bhatia S, Lipson E, Kudchadkar R, Miller N, Annamalai L . PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016; 374(26):2542-52. PMC: 4927341. DOI: 10.1056/NEJMoa1603702. View

15.

Mahmood S, Chen C, Shapnik N, Krishnan U, Singh H, Makker V . Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report. Gynecol Oncol Rep. 2018; 25:74-77. PMC: 6005798. DOI: 10.1016/j.gore.2018.05.014. View

16.

Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Grohe C . Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. Lung Cancer. 2016; 99:117-9. DOI: 10.1016/j.lungcan.2016.06.025. View

17.

Hellmann M, Nathanson T, Rizvi H, Creelan B, Sanchez-Vega F, Ahuja A . Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell. 2018; 33(5):843-852.e4. PMC: 5953836. DOI: 10.1016/j.ccell.2018.03.018. View

18.

Aretz H . Myocarditis: the Dallas criteria. Hum Pathol. 1987; 18(6):619-24. DOI: 10.1016/s0046-8177(87)80363-5. View

19.

Gibson R, Delaune J, Szady A, Markham M . Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep. 2016; 2016. PMC: 4964148. DOI: 10.1136/bcr-2016-216228. View

20.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey C, Lao C . Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23-34. PMC: 5698905. DOI: 10.1056/NEJMoa1504030. View